Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Recruiting

Phase 2

Phase 3

TideglusibSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Sponsor:

AMO Pharma Limited

Code:

NCT05004129

Conditions

Congenital Myotonic Dystrophy

Eligibility Criteria

Sex: All

Age: 6 - 45

Healthy Volunteers: Not accepted

Interventions

Tideglusib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by AMO Pharma Limited on 2023-11-08.